HIGHER-RISK MYELODYSPLASTIC SYNDROME
Clinical trials for HIGHER-RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HIGHER-RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for HIGHER-RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough blood cancers: first human trial of GEN3018 begins
Disease control Recruiting nowThis early-stage trial tests a new antibody drug, GEN3018, in people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or stopped responding to treatment. The main goal is to check safety and find the best dose. Up to 78 participants will…
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for high-risk MDS patients: phase 3 trial launched
Disease control Recruiting nowThis study tests whether adding the experimental drug lisaftoclax to standard chemotherapy (azacitidine) helps people with a newly diagnosed, aggressive form of myelodysplastic syndrome (HR-MDS) live longer. About 490 adults worldwide will be randomly assigned to receive either t…
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New hope for blood cancer patients: experimental drug CCS1477 enters trials
Disease control Recruiting nowThis study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. The goal is to see if the drug is safe and can help control the disease. About 250 participants who have tried standard treatments without s…
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated May 05, 2026 11:52 UTC